3,112 Shares in Natera, Inc. (NASDAQ:NTRA) Acquired by Lake Hills Wealth Management LLC

Lake Hills Wealth Management LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 3,112 shares of the medical research company's stock, valued at approximately $440,000. Natera makes up approximately 0.3% of Lake Hills Wealth Management LLC's holdings, making the stock its 27th biggest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. LRI Investments LLC purchased a new stake in Natera in the fourth quarter valued at approximately $29,000. Blue Trust Inc. raised its position in Natera by 104.3% in the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock worth $30,000 after acquiring an additional 97 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after buying an additional 261 shares in the last quarter. Principal Securities Inc. increased its position in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after buying an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC boosted its stake in shares of Natera by 1,328.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after acquiring an additional 332 shares during the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Performance

Shares of NTRA stock traded up $1.03 during trading on Tuesday, reaching $165.22. 1,188,866 shares of the company's stock were exchanged, compared to its average volume of 1,406,388. The firm's fifty day moving average price is $152.72 and its 200-day moving average price is $158.56. The stock has a market capitalization of $22.56 billion, a PE ratio of -93.88 and a beta of 1.74. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. Natera, Inc. has a twelve month low of $92.14 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company's revenue was up 36.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.56) earnings per share. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have issued reports on NTRA shares. Royal Bank of Canada started coverage on Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. UBS Group raised their target price on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Robert W. Baird raised their price objective on Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. Piper Sandler lifted their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Thursday, May 15th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. One research analyst has rated the stock with a sell rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $184.63.

Insiders Place Their Bets

In other Natera news, Director Gail Boxer Marcus sold 4,000 shares of the business's stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total value of $590,760.00. Following the transaction, the director now owns 9,704 shares of the company's stock, valued at approximately $1,433,183.76. The trade was a 29.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Solomon Moshkevich sold 1,026 shares of the company's stock in a transaction on Monday, March 17th. The shares were sold at an average price of $146.04, for a total value of $149,837.04. Following the transaction, the insider now directly owns 144,782 shares in the company, valued at $21,143,963.28. This represents a 0.70% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 68,275 shares of company stock worth $10,075,783. 7.60% of the stock is owned by corporate insiders.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.